Drugs / linsitinib
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01567384 | May 2012 → Oct 2013 | cancer | Emory University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01529684 | Mar → Dec 2012 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01154335 | Jul 2010 → May 2013 | metastatic malignant neoplasm in the colon | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01016860 | Dec 2009 → Apr 2013 | colorectal cancer | University of Colorado, Denver | Terminated | No outcome recorded |
| Phase 1 | NCT00739453 | Oct 2008 → Mar 2012 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00514306 | Jul 2007 → Sep 2010 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00514007 | Jun 2007 → Mar 2012 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT01672736 | Sep 2012 → Mar 2017 | plasma cell myeloma | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 1/2 | NCT01465815 | Dec 2011 → Sep 2013 | lip and oral cavity squamous cell carcinoma, skin squamous cell carcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00889382 | Aug 2009 → Aug 2014 | ovarian cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT01600807 | — | pancreatic ductal adenocarcinoma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 211 trials · 2 missed | ||||||
| Phase 2 | NCT02057380 | Apr 2014 → Oct 2016 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02546544 | Mar 2014 → Jul 2016 | Ewing sarcoma | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01427205 | Jun 2013 → Jun 2016 | head and neck cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01560260 | Mar 2012 → Oct 2015 | Carney complex, chondrosarcoma, gastrointestinal stromal tumor, paraganglioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01533181 | Feb 2012 → Nov 2014 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT01533246 | Feb → Nov 2012 | hormone-resistant prostate carcinoma, prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT01221077 | Apr 2011 → Mar 2013 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01186861 | Mar 2011 → Jul 2013 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT01334710 | Mar → Aug 2011 | liver cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01101906 | Jan → Nov 2011 | hepatocellular carcinoma | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 2 | NCT01205685 | May 2010 → Jul 2011 | breast cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00924989 | Dec 2009 → Jul 2012 | adrenal cortex carcinoma | Astellas Pharma Inc | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT01013506 Background | Aug → Dec 2009 | breast cancer | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT06112340 Comparator | Oct 2023 → Jun 2026 overdue | Hashimoto thyroiditis, disease of orbital part of eye adnexa, exophthalmos | Sling Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05276063 Comparator | Jul 2022 → Oct 2024 | Hashimoto thyroiditis, disease of orbital part of eye adnexa, exophthalmos | Sling Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | linsitinib | “A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic...” PMID 25335932 ↗ Oct 2014 |
| Known as | ASP7487 | “ASP7487” NCT01672736 ↗ |
| Known as | LINSITINIB (OSI-906) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1091644 ↗ |
| Known as | OSI-906 | “A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma” NCT01672736 ↗ |
| Known as | OSI-906AA | ChEMBL registry synonym — accepted as the source's own label CHEMBL1091644 ↗ |
| Action | Inhibit | “small molecule inhibitor of both IGF-1R and the insulin receptor” PMID 25795408 ↗ Mar 20151“Insulin receptor inhibitor” CHEMBL1091644 ↗ |
| Modality | Small molecule | “oral small molecule inhibitor” PMID 25795408 ↗ Mar 2015 |
| Route | Oral | “OSI-906 administered orally” NCT00514007 ↗ |
| Target | IGF1R | “IGF-1R inhibitor OSI-906” NCT01013506 ↗ |
| Target | INSR | “Insulin receptor inhibitor” CHEMBL1091644 ↗ |